Medication Instructions for Patients: Dosage and Administration of Avatrombopag (Avatrombopag, Sucoxin)

Avatrombopag/Avatrombopag is mainly used to treat the following conditions:

1. Treatment of thrombocytopenia in patients with chronic liver disease (CLD): It is suitable for the treatment of thrombocytopenia in adult patients with chronic liver disease who plan to undergo surgery.

2. Treatment of thrombocytopenia in patients with chronic immune thrombocytopenia (ITP): It is suitable for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an inadequate response to previous treatment.

3. Usage and dosage:

1. Medication management: Obtain platelet counts from patients before treatment with avatrombopag and on the day of surgery to ensure an appropriate increase in platelet counts. Assess platelet counts weekly until a stable platelet count is ≥50×10^9/L, then obtain platelet counts monthly. After discontinuing avatrombopag, obtain platelet counts weekly for at least 4 weeks. Do not use avatrombopag to normalize platelet counts.

2. Recommended dosage:

(1) Thrombocytopenia in patients with chronic liver disease (CLD): Begin administration of avatropopag 10 to 13 days before planned surgery. The recommended daily dose is based on the patient's blood count before planned surgery. For plate count, when the patient's platelet count is <40×10^9/L, take 60 mg (3 tablets) orally once a day; when the patient's platelet count is 40-50×10^9/L, take 40 mg (2 tablets) orally once a day for 5 days. Patients should have surgery 5 to 8 days after the last dose of avatropopag.

(2) Thrombocytopenia in patients with chronic immune thrombocytopenia (ITP): The starting dose of avatrombopag is 20 mg (1 tablet) once daily, taken with food. If necessary, use the lowest dose of avatrombopag required to achieve and maintain a platelet count of ≥50×10^9/L, thereby reducing the risk of bleeding. The daily dose shall not exceed 40 mg.

(3) Discontinuation:If the platelet count does not increase to ≥50×10^9/L after 4 weeks of administration, discontinue avatropopag . The maximum dose is 40 mg once daily. If the platelet count is >400×109/L after 2 weeks of 20 mg administration once a week, discontinue avatropopag.

3. Combined medication: If avatrombopag is used in combination with a moderate or severe dual inhibitor of CYP2C9 and CYP3A4, take 20 mg (1 tablet) three times a week; if it is used with a moderate or strong dual inducer of CYP2C9 and CYP3A4, take 40 mg of avatrombopag (2 tablets) once a day.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e2d5960d-6c18-46cc-86bd-089222b09852